Logo image of SILK

SILK ROAD MEDICAL INC (SILK) Stock Fundamental Analysis

NASDAQ:SILK - Nasdaq - US82710M1009 - Common Stock - Currency: USD

27.49  -0.01 (-0.04%)

After market: 27.49 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SILK. SILK was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of SILK is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SILK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SILK had negative earnings in the past year.
In the past year SILK has reported a negative cash flow from operations.
SILK had negative earnings in each of the past 5 years.
In the past 5 years SILK always reported negative operating cash flow.
SILK Yearly Net Income VS EBIT VS OCF VS FCFSILK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

SILK has a Return On Assets of -20.96%. This is comparable to the rest of the industry: SILK outperforms 51.87% of its industry peers.
SILK has a Return On Equity of -36.55%. This is comparable to the rest of the industry: SILK outperforms 54.01% of its industry peers.
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROIC N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
SILK Yearly ROA, ROE, ROICSILK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

SILK has a better Gross Margin (74.28%) than 85.03% of its industry peers.
In the last couple of years the Gross Margin of SILK has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SILK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
SILK Yearly Profit, Operating, Gross MarginsSILK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

SILK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SILK has more shares outstanding
SILK has more shares outstanding than it did 5 years ago.
SILK has a worse debt/assets ratio than last year.
SILK Yearly Shares OutstandingSILK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SILK Yearly Total Debt VS Total AssetsSILK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

SILK has an Altman-Z score of 4.49. This indicates that SILK is financially healthy and has little risk of bankruptcy at the moment.
SILK's Altman-Z score of 4.49 is fine compared to the rest of the industry. SILK outperforms 72.73% of its industry peers.
SILK has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
SILK has a worse Debt to Equity ratio (0.49) than 64.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z 4.49
ROIC/WACCN/A
WACC8.47%
SILK Yearly LT Debt VS Equity VS FCFSILK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 7.63 indicates that SILK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.63, SILK belongs to the top of the industry, outperforming 85.56% of the companies in the same industry.
A Quick Ratio of 6.69 indicates that SILK has no problem at all paying its short term obligations.
The Quick ratio of SILK (6.69) is better than 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.63
Quick Ratio 6.69
SILK Yearly Current Assets VS Current LiabilitesSILK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SILK have decreased by -2.13% in the last year.
SILK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.54%.
The Revenue has been growing by 38.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%

3.2 Future

SILK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.87% yearly.
SILK is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.50% yearly.
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SILK Yearly Revenue VS EstimatesSILK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SILK Yearly EPS VS EstimatesSILK Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SILK. In the last year negative earnings were reported.
Also next year SILK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILK Price Earnings VS Forward Price EarningsSILK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILK Per share dataSILK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.37%
EPS Next 3Y3.9%

More info and screens

0

5. Dividend

5.1 Amount

SILK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILK ROAD MEDICAL INC

NASDAQ:SILK (9/16/2024, 8:00:02 PM)

After market: 27.49 0 (0%)

27.49

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-06 2024-11-06/amc
Inst Owners3.3%
Inst Owner Change-36.37%
Ins Owners28.49%
Ins Owner Change-19.72%
Market Cap1.12B
Analysts49.23
Price Target22.54 (-18.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.36%
Min EPS beat(2)-9.6%
Max EPS beat(2)12.31%
EPS beat(4)3
Avg EPS beat(4)8.54%
Min EPS beat(4)-9.6%
Max EPS beat(4)23.2%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)7
Avg EPS beat(12)1.66%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)1.28%
Max Revenue beat(2)6.4%
Revenue beat(4)3
Avg Revenue beat(4)3.97%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)10.41%
Revenue beat(8)6
Avg Revenue beat(8)3.67%
Revenue beat(12)9
Avg Revenue beat(12)2.91%
Revenue beat(16)12
Avg Revenue beat(16)2.27%
PT rev (1m)-2.14%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)-2.69%
EPS NY rev (3m)-2.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.22%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.83
P/FCF N/A
P/OCF N/A
P/B 7.22
P/tB 7.22
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS4.71
BVpS3.81
TBVpS3.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.28%
FCFM N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.1%
Cap/Sales 1.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.63
Quick Ratio 6.69
Altman-Z 4.49
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)251.08%
Cap/Depr(5y)187.13%
Cap/Sales(3y)3.05%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
EBIT growth 1Y-13.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.12%
EBIT Next 3Y19.7%
EBIT Next 5YN/A
FCF growth 1Y27.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.14%
OCF growth 3YN/A
OCF growth 5YN/A